Zolbetuximab is a monoclonal antibody that targets CLDN18.2, a biomarker of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab mediates tumor cell death via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.